Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

Click to increase image sizeClick to decrease image size

Acknowledgements

Dr. O’Connor is recipient of the American Cancer Society Research Professorship.

Authorship contributions

AS, HM and OAO wrote the manuscript. BC performed the statistical analysis. AS, CD, KJS, DV, MC, JMC, and OAO provided cases. All authors critically analyzed the data, reviewed the manuscript and contributed to the final version.

Disclosure statement

DV has received honoraria from Seattle Genetics, Lundbeck, Abbvie, Celgene, Janssen, AstraZeneca, Roche, and Nanostring. JMC received research support and honoraria from Seattle Genetics and Takeda Pharmaceuticals. OAO received research support from Spectrum, Celgene, Merck, Affimed, Seattle Genetics, and Scientific Advisory Role with Mundipharma. All other authors declare no competing interests.

Additional information

Funding

As received research support from Affimed and consultancy fees from Seattle Genetics, Gilead, and Daiichi Sanko. JK reports personal fees from Seattle Genetics and Lundbeck during the conduct of this study. JKL received research support and advisory board service from Kymera Therapeutics, research support from Denovo Biopharma, advisory board service from Astex Pharmaceuticals, and Speakers’ Bureau from AstraZeneca. EM received research support from Merck, Celgene, Spectrum, and Scientific Advisory Role with Mundipharma, Verastem, Spectrum, Myeloid Therapeutics. FM received research funding from Seattle Genetics.